In the interview with Life Science Review, NTC CEO Riccardo Carbucicchio highlighted NTC's commitment to producing drugs that fill patients' unmet medical needs, to research with large clinical trials, and to developing drugs that respect environmental, social, and governance (ESG) principles, and then following them up with distribution, which takes place globally through B2B partnerships.

Read the interview